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Introduction {#sec001}
============

Ecosystems of pathogens have been described with regard to a multitude of diseases \[[@pone.0216085.ref001]--[@pone.0216085.ref003]\]. The bacterium *Pseudomonas aeruginosa* and the fungus *Aspergillus fumigatus* form such an ecosystem, e.g. when chronically colonizing the lungs of cystic fibrosis (CF) individuals \[[@pone.0216085.ref004]--[@pone.0216085.ref007]\]. Both pathogens have been associated with deterioration of lung function \[[@pone.0216085.ref004]--[@pone.0216085.ref017]\], and their combined presence in airways of CF patients seems to aggravate disease progression \[[@pone.0216085.ref018],[@pone.0216085.ref019]\]. *P*. *aeruginosa* and *A*. *fumigatus* also are prominent opportunistic pathogens in immune-compromised patients, particularly in those with neutropenia \[[@pone.0216085.ref020],[@pone.0216085.ref021]\].

Previous studies have focused on *A*. *fumigatus* inhibition caused by *P*. *aeruginosa* products such as pyocyanin (5-N-methyl-1-hydroxyphenazine) \[[@pone.0216085.ref022]--[@pone.0216085.ref025]\], 1-hydroxyphenazine \[[@pone.0216085.ref022],[@pone.0216085.ref024],[@pone.0216085.ref025]\], phenazine-1-carboxamide and phenazine-1-carboxylic acid \[[@pone.0216085.ref025]\]. We recently reported that the *P*. *aeruginosa* product pyoverdine is the major mediator of *P*. *aeruginosa* inhibitory function towards *A*. *fumigatus* biofilms \[[@pone.0216085.ref026]\]. Pyoverdine, the major siderophore of *P*. *aeruginosa* \[[@pone.0216085.ref027],[@pone.0216085.ref028]\], strongly binds to iron, which is an essential co-factor for both *P*. *aeruginosa* and *A*. *fumigatus* \[[@pone.0216085.ref029]--[@pone.0216085.ref031]\]. Pyoverdine-bound iron is no longer available for *A*. *fumigatus*, starving *A*. *fumigatus* of iron, and resulting in fungistasis \[[@pone.0216085.ref026]\]. The question arose whether *A*. *fumigatus* could counteract *P*. *aeruginosa* inhibition. Here we provide evidence that *A*. *fumigatus* hydroxamate siderophores in times of iron shortage, created by a competing microbe, ensure availability of the essential co-factor iron exclusively to the fungus. Concomitantly, interference with *A*. *fumigatus* siderophore production renders the fungus more sensitive to anti-fungal effects of iron chelators, and possibly more sensitive even to effects of anti-fungal drugs not involved in iron chelation, like amphotericin B.

Materials and methods {#sec002}
=====================

Materials {#sec003}
---------

Pyoverdine (PYOV), 3-hydroxy-1,2-dimethyl-4(1H)pyridine (deferiprone, DFP), celastrol, 2,3-bis\[2-methoxy-4-nitro-5-sulfophenyl\]-2H-tetrazolium-5-carboxanilide inner salt (XTT), and menadione were purchased from Sigma-Aldrich (St. Louis, MO). Amphotericin B (AmB) was derived from X-Gen Pharmaceuticals Inc. (Horseheads, NY). Chrome Azurol S (CAS) was purchased from MP Biomedicals (Solon, OH). Ferri- and desferri-triacetylfusarinine C (TAFC, DF-TAFC) were purified as described previously \[[@pone.0216085.ref032]\].

Isolates {#sec004}
--------

All isolates used in this study are summarized in [Table 1](#pone.0216085.t001){ref-type="table"}.
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###### Isolates used in this study.

![](pone.0216085.t001){#pone.0216085.t001g}

  Organism            Isolate        Description                                                                                       ATCC    Reference
  ------------------- -------------- ------------------------------------------------------------------------------------------------- ------- ---------------------------------------------------
  *A*. *fumigatus*    10AF           Virulent patient isolate                                                                          90240   \[[@pone.0216085.ref033],[@pone.0216085.ref034]\]
  *A*. *fumigatus*    AF13073        Parental strain for AfΔ*sidA*                                                                     13073   
  *A*. *fumigatus*    AfΔ*sidA*      [l]{.smallcaps}-ornithine-*N* ^5^-mono-oxygenase deficient *A*. *fumigatus* mutant strain                 \[[@pone.0216085.ref035]\]
  *A*. *fumigatus*    AF46645        Parental strain for AfΔ*sidC* and AfΔ*sidF*                                                       46645   
  *A*. *fumigatus*    AfΔ*sidC*      Deficient for the hydroxamate siderophores ferricrocin (FC) and hydroxy-FC (HFC)                          \[[@pone.0216085.ref036]\]
  *A*. *fumigatus*    AfΔ*sidF*      Deficient for the hydroxamate siderophores fusarinine C (FsC) and triacetylfusarinine C (TAFC).           \[[@pone.0216085.ref036]\]
  *A*. *fumigatus*    AfS77          Derivate of ATCC 46645                                                                                    \[[@pone.0216085.ref037]\]
  *P*. *aeruginosa*   PA14           Parental strain for *pvdD-* and *pvdD-pchE-*                                                              \[[@pone.0216085.ref038]\]
  *P*. *aeruginosa*   *pvdD-*        Pyoverdine deficient mutant                                                                               \[[@pone.0216085.ref039]\]
  *P*. *aeruginosa*   *pvdD-pchE-*   Pyoverdine/pyochelin deficient mutant                                                                     \[[@pone.0216085.ref026]\]

The work flow for the following procedures is summarized in [S1 Fig](#pone.0216085.s001){ref-type="supplementary-material"}.*A*. *fumigatus* supernatant production {#sec005}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

*A*. *fumigatus* conidia were inoculated into RPMI 1640 medium (RPMI, Lonza, Walkersville, MD) at 2.5x10^4^ conidia/ml. *A*. *fumigatus* suspensions were incubated at 37°C for 48h ([S1 Fig](#pone.0216085.s001){ref-type="supplementary-material"}). *A*. *fumigatus* supernatants (Afsup) were filtered (0.22 μm) for sterility after the growth period.

*Pseudomonas* supernatant production and pyoverdine measurement {#sec006}
---------------------------------------------------------------

PA14 supernatants were prepared as detailed previously \[[@pone.0216085.ref040]\]. Briefly, *P*. *aeruginosa* \[5 x 10^7^ cells/ml\] was inoculated into RPMI 1640 medium, or mixtures of RPMI and Afsup, and incubated at 37°C for 24h. Bacterial growth was measured at 600 nm with a spectrophotometer (Genesys 20, Thermo Fisher Scientific Inc., Waltham, MA). Bacterial cultures were centrifuged at 200 x *g* for 30 min at room temperature, and filtered (0.22 μm). Pyoverdine production in the supernatant was measured as described previously \[[@pone.0216085.ref041]\] at 405 nm. Pyoverdine measurements were normalized to bacterial growth using the formula: Relative PYOV expression = OD405 / OD600. At the concentrations used in this study, pyoverdine, a colored substance, did not interfere with the colorimetric XTT assay used for determination of fungal metabolism. PYOV concentrations in undiluted *P*. *aeruginosa* supernatants are about 30 μM. Pyoverdine concentrations in sputum have been shown to be between 0.3 and 51 μM \[[@pone.0216085.ref042]\].

Assay for the measurement of metabolism of *A*. *fumigatus* forming (BCAM assay, Bioassay-Conidia-Agar-Metabolic) or preformed (BHAM assay, Bioassay-Hyphae-Agar-Metabolic) biofilms {#sec007}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BCAM and BHAM assays were performed as described previously \[[@pone.0216085.ref026]\]. In these assays, *A*. *fumigatus* grows out into biofilms covering the agar surface. Briefly, RPMI agar containing 2.5x10^4^ to 10^5^ *A*. *fumigatus* conidia/ml agar (as specified for different experiments in the Results section) was distributed into sterile flat-bottom 96 well cell culture plates (COSTAR, Corning, NY) at 100 μl/well. Upon agar solidification, wells were either incubated at 37°C for 24 hours before loading (= BHAM assays), or immediately loaded with 100 μl of test substances (= BCAM assays). Control wells on each test plate contained 100 μl of RPMI 1640 medium, allowing the conversion of test results to % of the RPMI control (= 100%). Loaded plates were incubated at 37°C for 24 hours. Fungal metabolism was determined by XTT metabolic assay at 490 nm \[[@pone.0216085.ref040],[@pone.0216085.ref043]\]. Menadione (vitamin K3) was used as an ingredient in the XTT metabolic assay, boosting the reduction of tetrazolium salts to formazans. XTT assays were evaluated using a plate reader (Opsys MR, DYNEX Technologies, Chantilly, VA). Although XTT is a measure of metabolic activity of cells, previous studies of *A*. *fumigatus* have indicated that XTT results are linear with mass, and equated XTT result with dry weight \[[@pone.0216085.ref044]--[@pone.0216085.ref046]\].

*Aspergillus* growth assays {#sec008}
---------------------------

AfΔ*sidA* (10^4^conidia) was point-inoculated on 2 ml solid minimal medium \[[@pone.0216085.ref047]\] in the presence of 50--600 μl PA14 wildtype or PA14 PaΔ*pvdD* bacterial supernatant with or without supplementation of FeSO~4~ \[1 μM\]. Radial fungal growth was scored after incubation of the plates for 48 hours at 37°C.

Chrome azurol S (CAS) assay {#sec009}
---------------------------

For measurement of siderophore production 10x CAS assay reagent was prepared as described previously \[[@pone.0216085.ref048]\]. One part 10x CAS reagent was combined with 9 parts Afsups in RPMI, and incubated at 37°C for 24 hours. Mixtures were measured using the plate reader, and compared to RPMI not containing CAS reagent or RPMI/1x CAS reagent as reference points.

Statistical analysis {#sec010}
--------------------

Results were analyzed using Student's *t* test, if two groups were compared, and by 1-way ANOVA, combined with a Tukey's post-test for multiple comparisons. Data reported as percentages of the control value were compared after arcsin transformation of the proportions \[[@pone.0216085.ref026]\]. All data in this study are expressed as a mean ± SD.The number of replicates in each assay is four or higher. Assays were repeated at least twice, and a representative experiment is shown. Supporting information on data sets used in this study is provided in [S1 Table](#pone.0216085.s006){ref-type="supplementary-material"}.

Results {#sec011}
=======

*A*. *fumigatus* supernatants induce pyoverdine production by *P*. *aeruginosa* {#sec012}
-------------------------------------------------------------------------------

Fungal supernatants (Afsup), produced by planktonic growth of *A*. *fumigatus* strain 10AF in RPMI (experimental setup described in [S1 Fig](#pone.0216085.s001){ref-type="supplementary-material"}), induced pyoverdine production by *P*. *aeruginosa* in a dose-dependent manner, with 10% Afsup still significantly inducing pyoverdine production. As pyoverdine is induced in response to iron shortage, increased pyoverdine production here suggests sequestration of iron from the growth medium by Afsup ([Fig 1A](#pone.0216085.g001){ref-type="fig"}).

![*A*. *fumigatus* supernatant effects on *P*. *aeruginosa growth and pyoverdine production*.\
Planktonic 10AF supernatant (10AFsup) was diluted in RPMI from 50% to 0% 10AFsup, and incubated with *P*. *aeruginosa* cells (5x10^7^/ml) at 37°C for 24h. Relative pyoverdine (PYOV) concentrations (A) were calculated using the quotient A405 (PYOV)/A600 (bacterial growth: B). Supernatants shown in A and B, as well as PA14 supernatant not containing 10Afsup, were compared with respect to their activities on 10AF forming biofilm (C: BCAM) or preformed biofilm (D: BHAM) metabolism. E: 10AF forming biofilm was incubated with 10 or 25% PA14 wildtype supernatant with or without the addition of 25% 10AFsup for 24 hours. Effects on 10AF forming biofilm metabolism were evaluated by XTT assay. F: 10AF forming biofilm was incubated with 5 or 10 μM pyoverdine (PYOV) with or without the addition of 25% 10AFsup for 24 hours. Effects on 10AF forming biofilm metabolism were evaluated by XTT assay. Statistics for A and B: 1way ANOVA, RPMI (white bar) vs. all groups containing Afsup (black bars). Statistics for C and D: 1way ANOVA, PA14 supernatant (white striped bar) vs. PA14 supernatant containing 10AFsup (grey striped bars). Other comparisons by t-Test as indicated by the ends of the brackets. Statistics for E and F: t-Test, RPMI (white bar) vs. all other bars. Other comparisons as indicated by the ends of the brackets. One, two or three asterisks = p ≤ 0.05, p ≤ 0.01 or p ≤ 0.001, respectively.](pone.0216085.g001){#pone.0216085.g001}

Concentrations of Afsup higher than 10% interfered with bacterial growth in a concentration-dependent manner ([Fig 1B](#pone.0216085.g001){ref-type="fig"}). As iron is a major co-factor for microbial growth, the reason for inhibitory effects of Afsup on *P*. *aeruginosa* growth might be a reaction to iron denial. Although gliotoxin has been suggested as an anti-microbial factor \[[@pone.0216085.ref049]\], in our hands supernatants produced by an *A*. *fumigatus* mutant unable to produce gliotoxin \[[@pone.0216085.ref050]\] affected *P*. *aeruginosa* growth to a similar degree as supernatants produced by its parent ([S2 Fig](#pone.0216085.s002){ref-type="supplementary-material"}). Distilled water (25%), instead of Afsup (25%) during *P*. *aeruginosa* supernatant preparation did not result in interference with *P*. *aeruginosa* effects on *A*. *fumigatus* biofilm metabolism, indicating that *P*. *aeruginosa* supernatant dilution by Afsups was not the reason for the protective effects of Afsups ([S3 Fig](#pone.0216085.s003){ref-type="supplementary-material"}).

In order to verify that Afsup indeed induced production of pyoverdine, we used a PA14 mutant not able to produce pyoverdine (PaΔ*pvdD*) \[[@pone.0216085.ref039]\]. With or without the presence of Afsup, PaΔ*pvdD* supernatant did not absorb at 405 nm, confirming that Afsup did not induce production of an unknown *P*. *aeruginosa* product detectable at 405 nm ([S4A Fig](#pone.0216085.s004){ref-type="supplementary-material"}).

Afsup protects *A*. *fumigatus* forming biofilm from *P*. *aeruginosa* anti-fungal activity and pure pyoverdine {#sec013}
---------------------------------------------------------------------------------------------------------------

Pyoverdine has detrimental effects on Af biofilm metabolism \[[@pone.0216085.ref026]\]. Surprisingly, although containing high concentrations of pyoverdine ([Fig 1A](#pone.0216085.g001){ref-type="fig"}), *P*. *aeruginosa* supernatants produced in the presence of Afsup were less inhibitory for forming ([Fig 1C](#pone.0216085.g001){ref-type="fig"}) or preformed ([Fig 1D](#pone.0216085.g001){ref-type="fig"}) *A*. *fumigatus* biofilms than *P*. *aeruginosa* supernatants produced without Afsups,whereas Afsups up to 50% did not affect *A*. *fumigatus* biofilms when administered alone. Similarly, when *P*. *aeruginosa* supernatants and Afsups were prepared separately, their combination was less inhibitory to *A*. *fumigatus* biofilms than *P*. *aeruginosa* supernatant alone ([Fig 1E](#pone.0216085.g001){ref-type="fig"}).

Presumably owing to their lack of pyoverdine production, supernatants of PaΔ*pvdD* were less inhibitory to 10AF biofilms than PA14 supernatants. The presence of Afsup further decreased the inhibitory activity of PaΔ*pvdD* supernatants to RPMI control levels ([S4B Fig](#pone.0216085.s004){ref-type="supplementary-material"}). Protective Afsup effects were also observed when Afsups were combined with pure pyoverdine ([Fig 1F](#pone.0216085.g001){ref-type="fig"}).

Taken together, these data indicate that despite its ability to induce pyoverdine production by *P*. *aeruginosa*, Afsup protects *A*. *fumigatus* biofilms.

Stability of protective Af supernatant effects {#sec014}
----------------------------------------------

In order to determine the reason for protection of A. fumigatus biofilms by Afsup, we first tested stability of 10AFsup to heat, and long-term storage. 10AFsup was heated to 56°C or 90°C for 30 minutes, or subjected to three freeze-thaw cycles. Treated or untreated 10AFsups were diluted to 25%, combined with *P*. *aeruginosa* supernatants, and tested for effects on *A*. *fumigatus* biofilm metabolism. Our results show that heat does not destroy the protective compound in Afsup ([Fig 2A](#pone.0216085.g002){ref-type="fig"}). Repeated freeze-thaw cycles diminished, but did not abolish protection ([Fig 2A](#pone.0216085.g002){ref-type="fig"}). We also kept 10AFsup at 4°C for 12 months, and measured protection from pyoverdine every 3 months. The protective potential of Afsup was almost constant over the 12 months period ([Fig 2B](#pone.0216085.g002){ref-type="fig"}). When 10AFsup was kept at room temperature for 12 months, protection was marginally lower, but still significant ([Fig 2B](#pone.0216085.g002){ref-type="fig"}). Taken together, our data suggest that the protective compound in 10AFsup is stable.

![Stability of Afsup.\
A: Mixtures (25%) of freshly prepared 10AFsup in RPMI were kept at 4°C, or heated to 56°C or 90°C for 30 minutes, or subjected to 3 freeze-thaw cycles. Treated 10AFsups (25% in RPMI), were combined with 20% *P*. *aeruginosa* supernatants, and tested for effects on *A*. *fumigatus* forming biofilm metabolism. B: 10AFsup was stored at 4°C for up to 12 months, and tested for protective activity against 5 μM pyoverdine (PYOV) every 3 months. A portion of the 10AFsup was stored at room temperature (RT), and tested after 12 months of storage. Protective activity was tested using a BCAM assay. Statistics for A: t-Test, PA14 supernatant (grey bar) vs. all other bars. Other comparisons as indicated by the ends of the brackets. \* indicate significant increases, ▪ indicate significant decreases. Statistics for B: t-Test, pyoverdine (white striped bar) vs. all other bars. One, two or three asterisks or squares = p ≤ 0.05, p ≤ 0.01 or p ≤ 0.001, respectively.](pone.0216085.g002){#pone.0216085.g002}

*A*. *fumigatus* siderophores protect *A*. *fumigatus* biofilm from *P*. *aeruginosa* anti-fungal activity {#sec015}
----------------------------------------------------------------------------------------------------------

Knowing that iron is a crucial factor for *A*. *fumigatus* biofilm, that pyoverdine inhibitory activity is owing to withholding iron from the fungus, and that the protective compound in Afsup is stable ([Fig 2](#pone.0216085.g002){ref-type="fig"}), we investigated the hypothesis that the protective compound might be an *A*. *fumigatus* siderophore. We produced supernatant of an *A*. *fumigatus* mutant lacking *sidA*, a gene crucial for the production of all four hydroxamate siderophores (AfΔ*sidAs*up), and compared to wildtype Afsup, produced by the AfΔ*sidA* parent AF13073 (AF13073sup). A CAS assay confirmed the lack of siderophores in AfΔ*sidA*sup ([Fig 3A](#pone.0216085.g003){ref-type="fig"}). Dilutions (25%) of AF13073sup and AfΔ*sidA*sup were incubated with PA14 or PaΔ*pvdD*. AF13073sup stimulated pyoverdine production by PA14 significantly more than AfΔ*sidA* sup ([Fig 3B](#pone.0216085.g003){ref-type="fig"}). AfΔ*sidA*sup also showed less protection for *A*. *fumigatus* biofilm against *P*. *aeruginosa* anti-fungal activity than AF13073sup ([Fig 3C](#pone.0216085.g003){ref-type="fig"}). When siderophore-deficient fungus was treated with pyoverdine, significant damage was induced ([Fig 3D](#pone.0216085.g003){ref-type="fig"}), whereas Afsup derived from either 10AF or AF13073 wildtype strains protected AfΔ*sidA* from pyoverdine-induced damage ([Fig 3D](#pone.0216085.g003){ref-type="fig"}). It has to be noted that neither the absence of pyoverdine nor the presence of Afsup from siderophore-deficient fungus prevented *P*. *aeruginosa* anti-fungal activity completely.

![*A*. *fumigatus* siderophores protect *A*. *fumigatus* biofilm from *P*. *aeruginosa* anti-fungal activity.\
A: Planktonic supernatants produced by an *A*. *fumigatus* mutant lacking hydroxamate siderophore production (AfΔ*sidA*) or its parental strain (AF13073) were subjected to siderophore production measurement by CAS assay. B: RPMI, or 25% AfΔ*sidA* or AF13073 supernatant in RPMI, were inoculated with PA14 wildtype or the PA14 mutant PaΔ*pvdD* \[5x10^7^ cells/ml\], and incubated at 37°C for 24h. Pyoverdine production was measured. C: Supernatants obtained in B (middle and right sets of 3 bars), as well as 25% AfΔ*sidA* or AF13073 supernatants in RPMI (left 3 bars) were tested for activity against *A*. *fumigatus* biofilm formation. D: AfΔ*sidA* forming biofilm was incubated with 5 μM pyoverdine (PYOV) with or without the addition of 25% 10AFsup or AF13073sup for 24 hours. Effects on forming biofilm metabolism were evaluated by XTT assay. Statistics: t-Test. Comparisons without brackets: B: RPMI vs. *A*. *fumigatus* supernatants for each bacterial strain. C: RPMI vs. all other bars. D: RPMI (leftmost white bar) vs. all other bars. Other comparisons as indicated by the ends of the brackets. \* indicate significant decreases, ▪ indicate significant increases. One, two, or three asterisks or squares = p ≤ 0.05, or p ≤ 0.01, or p ≤ 0.001, respectively.](pone.0216085.g003){#pone.0216085.g003}

In comparison to wildtype *A*. *fumigatus*, AfΔ*sidA* has a growth disadvantage due to missing Fe^3+^ uptake, which requires siderophores. 10AF or AF13073 wildtype supernatants, containing siderophores and iron, partially compensated AfΔ*sidA* disadvantages, as indicated by higher XTT values for AfΔ*sidA* in the presence of Afsups ([Fig 3D](#pone.0216085.g003){ref-type="fig"}). In conclusion, *A*. *fumigatus* siderophores are able to protect *A*. *fumigatus* biofilms against *P*. *aeruginosa* anti-fungal activity. [Fig 3C](#pone.0216085.g003){ref-type="fig"} also shows that AfΔ*sidA* sup was able to provide protection for *A*. *fumigatus* biofilm from PaΔ*pvdD* supernatant, whereas there was no protection against PA14 wildtype sup by either Afsup. This finding indicates that *A*. *fumigatus* hydroxamate siderophores are crucial for protection from detrimental pyoverdine effects, but that Afsup seems to contain other compounds which are able to protect *A*. *fumigatus* biofilm when the Pasup challenge lacks the powerful inhibitor pyoverdine.

AfΔ*sidA* is more sensitive to *P*. *aeruginosa* anti-fungal activity and pyoverdine than its wildtype {#sec016}
------------------------------------------------------------------------------------------------------

AfΔ*sidA-*derived supernatants were significantly less protective against pyoverdine than wildtype supernatants ([Fig 4A](#pone.0216085.g004){ref-type="fig"}). AfΔ*sidA* is lacking the intracellular hydroxamate siderophores ferricrocin (FC) and hydroxy-ferricrocin (HFC), as well as the extracellular hydroxamate siderophores fusarinin C (FsC) and triacetylfusarinine C (TAFC). Using *A*. *fumigatus* mutants with specific mutations in intracellular (AfΔ*sidC*), or extracellular hydroxamate siderophores (AfΔ*sidF*), we found that a lack of extracellular siderophores significantly interfered with protection from pyoverdine by *A*. *fumigatus* supernatants ([Fig 4A](#pone.0216085.g004){ref-type="fig"}). Protective effects of AfΔ*sidF* sup were significantly higher than protective effects of AfΔ*sidA* sup ([Fig 4A](#pone.0216085.g004){ref-type="fig"}), indicating that there might be some contribution to protection by other molecules missing in AfΔ*sidA* sup. [Fig 4A](#pone.0216085.g004){ref-type="fig"} also shows that supernatants, derived from three different *A*. *fumigatus* wildtypes (AF13073, AF46645, AfS77) protected forming biofilm of a fourth *A*. *fumigatus* wildtype (10AF), indicating that protection is not strain specific.

![AfΔ*sidA* is more sensitive towards PA14 or pure pyoverdine than its wildtype.\
A: Mixtures (25%) of freshly prepared AF13073, AfΔ*sidA*, AF46645, AfΔ*sidC*, AfΔ*sidF*, or AfS77 supernatants were combined with pyoverdine \[10 μM\], and tested for effects on 10AF forming biofilm metabolism. Fungal metabolism was measured by XTT assay. Measurements for controls (no pyoverdine) in each group were regarded as 100%. Statistics: t-Test, for each group: no pyoverdine (grey bar) vs. pyoverdine (black bar). Other comparison as indicated by the ends of the bracket. B: AF13073, AfΔ*sidA*, AF46645, AfΔ*sidC*, AfΔ*sidF* or AfS77 BCAM assays were incubated with either RPMI, PA14 supernatant, or 5 μM pyoverdine. Fungal metabolism was measured by XTT assay. For each fungus RPMI control measurements were regarded as 100%. Statistics: t-Test, comparison: RPMI (white bars) vs. PA14 supernatant (grey bars), or pyoverdine (black bars) for each fungus. Other comparisons as indicated by the ends of the brackets. C: A 10AF BCAM assay was incubated with either RPMI, pyoverdine \[10 μM\], TAFC \[5 or 10 μM\], DF-TAFC \[5 or 10 μM\], or combinations of pyoverdine and TAFC or DF-TAFC. Fungal metabolism was measured by XTT assay. RPMI control measurements were regarded as 100%. Statistics: t-Test, comparison: RPMI (white bar) vs. all other bars. Other comparisons as indicated by the ends of the brackets. One, two or three asterisks = p ≤ 0.05, p ≤ 0.01 or p ≤ 0.001, respectively.](pone.0216085.g004){#pone.0216085.g004}

PA14 supernatants, prepared in RPMI, as well as pure pyoverdine, were significantly more inhibitory during the formation of *A*. *fumigatus* biofilms derived from AfΔ*sid*A conidia than they were for biofilms derived from AF13073 conidia ([Fig 4B](#pone.0216085.g004){ref-type="fig"}). *A*. *fumigatus* mutants lacking either intracellular (AfΔ*sidC*), or extracellular hydroxamate siderophores (AfΔ*sidF*) showed increased sensitivity to PA14 supernatants or pure pyoverdine, compared to their wildtype AF46645 ([Fig 4B](#pone.0216085.g004){ref-type="fig"}). The loss of extracellular hydroxamate siderophores was more important for sensitivity than the loss of intracellular hydroxamate siderophores ([Fig 4B](#pone.0216085.g004){ref-type="fig"}). Using pure TAFC, or desferri-TAFC (DF-TAFC) we found complete protection from pyoverdine anti-fungal activity ([Fig 4C](#pone.0216085.g004){ref-type="fig"}), confirming the importance for *A*. *fumigatus* siderophores for protection from *P*. *aeruginosa* anti-fungal activity.

As observed in [Fig 2](#pone.0216085.g002){ref-type="fig"}, the protective compound in Afsup was stable to prolonged heat treatment (90°C, 30 min.). After being subject to the same treatment pure TAFC and DF-TAFC still significantly protected from pyoverdine toxicity ([S5 Fig](#pone.0216085.s005){ref-type="supplementary-material"}), further supporting the assumption that *A*. *fumigatus* siderophores are the protective compound in Afsup. It was also noted that pyoverdine was heat stable ([S5 Fig](#pone.0216085.s005){ref-type="supplementary-material"}).

The absence of A. fumigatus hydroxamate siderophores might have therapeutic relevance {#sec017}
-------------------------------------------------------------------------------------

Compared to wildtype *A*. *fumigatus* (AF13073), AfΔ*sid*A growth on plate was more affected with the highest concentration (600 μl) of PA14 supernatant blocking growth ([Fig 5A](#pone.0216085.g005){ref-type="fig"}). Likewise, the IC50 of pyoverdine for AF13073-derived forming biofilm was about 4 times higher than the IC50 for AfΔ*sid*A-derived forming biofilm ([Fig 5B](#pone.0216085.g005){ref-type="fig"}). Recently, the iron chelator deferiprone (DFP), which similar to pyoverdine, exerts anti-fungal activity by denying iron from *A*. *fumigatus* biofilms, has been proposed to be useful in anti-fungal therapy \[[@pone.0216085.ref051],[@pone.0216085.ref052]\]. We tested effects of DFP on AfΔ*sidA*, or its wildtype, and found significantly higher sensitivity of *A*. *fumigatus* biofilms to DFP when siderophore production was missing ([Fig 5C](#pone.0216085.g005){ref-type="fig"}). Genetic inhibition of siderophore production also increased anti-fungal effects of amphotericin B (AmB), an anti-fungal agent used against serious fungal infections, not only by *Aspergillus*, but also by other fungi \[[@pone.0216085.ref053]\], on *A*. *fumigatus* forming biofilm metabolism ([Fig 5D](#pone.0216085.g005){ref-type="fig"}).

![Absence of hydroxamate siderophores sensitizes *A*. *fumigatus*.\
A: RPMI was inoculated with PA14 \[5x10^7^ cells/ml\], incubated for 24 hours, and the culture supernatant was sterile filtered. Growth of point inoculated AF13073 or AfΔ*sidA* (10^4^conidia) on 3 ml solid minimal medium in the presence of 1 μM FeSO~4~ plus 50--600 μl of the sterile filtered supernatants was compared after incubation for 48 h at 37°C. B: AfΔ*sidA* (white bars) or AF13073 (black bars) BCAM assays were incubated with either RPMI or different concentrations of pyoverdine. Fungal metabolism was measured by XTT assay. Statistics: t-Test. For each fungus RPMI controls were regarded as 100%. RPMI controls for each fungus vs. all pyoverdine concentration. Other comparisons as indicated by the ends of the brackets. C: Wildtype (AF13073) or AfΔ*sidA* forming biofilms were incubated with DFP \[0.125--2 mM\] at 37°C for 24 hour. Fungal metabolism was measured by XTT assay. Statistics: t-Test, RPMI vs. all other bars of the same group. Other comparisons as indicated by the ends of the brackets. D: Wildtype (AF13073) or AfΔsidA forming biofilms were incubated with AmB \[19--312 ng/ml\] at 37°C for 24 hour. Fungal metabolism was measured by XTT assay. Statistics: t-Test, RPMI vs. all other bars of the same group. Other comparisons as indicated by the ends of the brackets. One, two or three asterisks = p ≤ 0.05, p ≤ 0.01 or p ≤ 0.001, respectively.](pone.0216085.g005){#pone.0216085.g005}

As a pharmacological complementation of our data obtained using AfΔ*sidA*, we investigated effects of the SidA-biosynthesis inhibitor celastrol \[[@pone.0216085.ref054]\]. Celastrol showed anti-fungal activity when used alone at concentrations above 5 μM ([Fig 6](#pone.0216085.g006){ref-type="fig"}). When combined with DFP, celastrol significant enhanced anti-fungal effects by DFP ([Fig 6](#pone.0216085.g006){ref-type="fig"}).

![Celastrol sensitizes *A*. *fumigatus* for anti-fungal activity of DFP.\
Forming wildtype *A*. *fumigatus* biofilm (10AF) was incubated with 1, 2.5, or 5 μM celastrol, 0.25--1 mM of DFP, or combinations of these two substances at 37°C for 24 hour. Fungal metabolism was measured by XTT assay. Statistics: t-Test. Bars without DFP (leftmost group) vs. all other bars with the same celastrol concentration. Other comparisons as indicated by the ends of the brackets. One, two or three asterisks = p ≤ 0.05, p ≤ 0.01 or p ≤ 0.001, respectively.](pone.0216085.g006){#pone.0216085.g006}

Discussion {#sec018}
==========

Fungal and bacterial biofilms e.g. frequently found co-inhabiting lungs of persons suffering from cystic fibrosis, represent a potentially severe pathogenicity factor. The present study mainly focuses on events during formation of *A*. *fumigatus* biofilm. In previous studies \[[@pone.0216085.ref040]\] and in studies by many others, it has been shown that biofilm formation by *A*. *fumigatus* is substantial within the first 16 hours of incubation. We have also performed many of the studies described in the present communication against fully formed *A*. *fumigatus* biofilms that develop over the subsequent 24 hours of incubation, and found the same phenomena, although to a lesser degree than in the earlier phase of *A*. *fumigatus* biofilm formation, as illustrated in [Fig 1C](#pone.0216085.g001){ref-type="fig"} vs. [1D](#pone.0216085.g001){ref-type="fig"}. This may suggest that iron is more important for the initial development of *A*. *fumigatus* biofilms.

The human body contains free iron levels of 10^−24^ M \[[@pone.0216085.ref055]\]. Free iron levels are decreased during infections due to increased levels of ferritin and the release of lactoferrin from neutrophils \[[@pone.0216085.ref056]\]. In the lungs of cystic fibrosis patients, *P*. *aeruginosa* and *A*. *fumigatus*, which both are crucially dependent on the availability of free iron for metabolism and growth, aggravate disease pathology \[[@pone.0216085.ref004]--[@pone.0216085.ref007]\]. Under low iron conditions, these organisms are forced to compete for resources in the same environment \[[@pone.0216085.ref029],[@pone.0216085.ref030]\].

As summarized in [Fig 7](#pone.0216085.g007){ref-type="fig"}, for *P*. *aeruginosa* as well as *A*. *fumigatus* a lack of iron is the signal to increase production of siderophores \[[@pone.0216085.ref027],[@pone.0216085.ref028]\]. Siderophores specifically chelate ferric iron with a high affinity \[[@pone.0216085.ref057]\]. Siderophores are of different types, based on the way the iron is complexed: phenolate-, catecholate-, hydroxamate-, carboxylate-, or mixed type of siderophores have been described \[[@pone.0216085.ref058]\].

![Summary.\
In need for iron *P*. *aeruginosa* (Pa) produces its siderophore pyoverdine (PYOV). PYOV-chelated iron is not available to *A*. *fumigatus* (Af), resulting in iron deficiency and damage to the fungus. Anti-fungal activity in part is counter-balanced by SidA-dependent *A*. *fumigatus* hydroxamate siderophores, providing iron to the fungus, further denying iron from *P*. *aeruginosa*.](pone.0216085.g007){#pone.0216085.g007}

The *P*. *aeruginosa* siderophore pyoverdine is a composite (mixed) siderophore comprising a peptide chain and a chromophore \[[@pone.0216085.ref059]\]. Pyoverdines bind iron with very high affinity, are able to acquire iron from transferrin, and their production is absolutely needed in mouse pulmonary infections \[[@pone.0216085.ref060]--[@pone.0216085.ref062]\]. We have described pyoverdine to be the *Pseudomonas*-derived key inhibitor of *A*. *fumigatus* in their intermicrobial competition via iron sequestration under low iron conditions \[[@pone.0216085.ref026]\]. We note that the loss of pyoverdine did not prevent *P*. *aeruginosa* anti-fungal activity completely, however. Pyochelin, the second siderophore of *P*. *aeruginosa*, is produced by all *P*. *aeruginosa* isolates, but its affinity for iron is much lower compared to pyoverdine \[[@pone.0216085.ref063],[@pone.0216085.ref064]\]. Pyoverdine does not act as a xenosiderophore for *A*. *fumigatus* \[[@pone.0216085.ref026]\], thus withholding iron from the fungus, and inducing anti-fungal effects \[[@pone.0216085.ref026]\]. *P*. *aeruginosa* does not seem to be able to use *A*. *fumigatus* siderophores either. Our results show that Afsups provoke increased pyoverdine production by *P*. *aeruginosa*, indicating that there is a paucity of iron in the medium. If *P*. *aeruginosa* could use iron bound to *A*. *fumigatus* siderophores, there would be an abundancy of iron available to the bacterium, and hence no increase in pyoverdine production. We here for the first time provide evidence that *A*. *fumigatus* is able to use iron bound to its hydroxamate siderophores as the main defense against *P*. *aeruginosa* competition for iron. These findings are summarized in [Fig 7](#pone.0216085.g007){ref-type="fig"}. Our results using *A*. *fumigatus* mutants defective in hydroxamate siderophore production also indicate that additional defense mechanisms might be in place, since supernatants derived from these mutants still partially protected from *P*. *aeruginosa* toxicity. Other microorganisms have developed defense mechanisms against *P*. *aeruginosa* not based on protective siderophore production. *Candida albicans* appears to defend itself against *P*. *aeruginosa* in part by down-regulating *P*. *aeruginosa* siderophore production \[[@pone.0216085.ref065]\].

Anti-bacterial *A*. *fumigatus* supernatant effects as a reason for protective effects against *P*. *aeruginosa* anti-fungal activity are highly unlikely. In the presence of Afsup, *P*. *aeruginosa* is able to even produce more pyoverdine, which requires functional bacterial metabolism. Also, Afsup protects from *P*. *aeruginosa* supernatants produced without Afsup being present, and Afsup, as well as pure *A*. *fumigatus* siderophores, protect from pure pyoverdine. Additionally, Afsups derived from a giotoxin mutant affected bacterial growth To the same degree as wildtype Afsups. The most plausible explanation for anti-bacterial effects of Afsups is depletion of essential factors in the medium, especially that of iron.

To overcome iron starvation, *A*. *fumigatus* produces its own siderophores \[[@pone.0216085.ref035]\]. *A*. *fumigatus* is able to produce four hydroxamate-containing siderophores: ferricrocin (FC) as well as hydroxyferricrocin (HFC) for intracellular iron trafficking, and fusarinine C (FsC) as well as its derivative triacetylfusarinine C (TAFC) for extracellular iron scavenging \[[@pone.0216085.ref036],[@pone.0216085.ref066],[@pone.0216085.ref067]\]. The first step in the biosynthesis of all four hydroxamate-containing siderophores is catalyzed by the enzyme L-ornithine N5-monooxygenase, termed SidA \[[@pone.0216085.ref030],[@pone.0216085.ref067]\]. SidA catalyzes oxygen and NADPH-dependent hydroxylation of L-ornithine to N5-L-hydroxyornithine, a crucial step for the biosynthesis of hydroxamate-containing siderophores \[[@pone.0216085.ref035]\]. In a similar fashion to *P*. *aeruginosa* siderophores, *A*. *fumigatus* siderophores are essential for pathogenesis, as the AfΔ*sidA* strain is unable to establish invasive aspergillosis in a mouse model \[[@pone.0216085.ref035],[@pone.0216085.ref056]\]. We show that in contrast to wildtype *A*. *fumigatus* supernatants, supernatants derived from AfΔ*sidA* were unable to protect *A*. *fumigatus* biofilms from detrimental effects of *P*. *aeruginosa* supernatants, or pyoverdine. This finding indicates the relevance of *A*. *fumigatus* siderophores for protection of *A*. *fumigatus* from *P*. *aeruginosa*-induced iron denial, and was supported by our finding that *A*. *fumigatus* siderophores (FC as well as TAFC) each could partially protect *A*. *fumigatus* from detrimental *P*. *aeruginosa* effects ([Fig 4A and 4B](#pone.0216085.g004){ref-type="fig"}). Pure preparations of the sideropore TAFC protected *A*. *fumigatus* from pyoverdine, even after heat treatment ([Fig 4C](#pone.0216085.g004){ref-type="fig"}, and [S5 Fig](#pone.0216085.s005){ref-type="supplementary-material"}). Protection by TAFC and its desferri form DF-TAFC was about equal, indicating that TAFC very efficiently binds free iron in medium, before pyoverdine can do the same. TAFC-bound iron does not seem to be transferable to pyoverdine, and exclusively is available to *A*. *fumigatus*.

*A*. *fumigatus* lacking hydroxamate siderophores, especially of the extracellular type, was more susceptible to pyoverdine ([Fig 4B](#pone.0216085.g004){ref-type="fig"}). The most pronounced detrimental effects of pyoverdine were observed when all four siderophores were missing.

A lack of siderophores, especially owing to a loss in SidA, renders the fungus more sensitive to iron denial by either pyoverdine ([Fig 5B](#pone.0216085.g005){ref-type="fig"}), or the clinically used iron chelator deferiprone (DFP, [Fig 5B](#pone.0216085.g005){ref-type="fig"}). Siderophore deficiency even sensitized the fungus to effects of amphotericin B (AmB, [Fig 5C](#pone.0216085.g005){ref-type="fig"}). While sensitization to DFP might be expected knowing that iron chelation by pyoverdine powerfully inhibits the fungus, sensitization to AmB is more surprising. It might be that a struggle for iron takes away energy from the fungus, and dampens intrinsic defense mechanisms, or that the membrane action of AmB \[[@pone.0216085.ref053]\] may adversely affect iron flux in the fungus.

As a pharmacological analog to *sidA* knockout we used celastrol treatment \[[@pone.0216085.ref054]\]. Celastrol, a pentacyclic triterpenoid that belongs to the family of quinone methides, exerts potent anti-cancer and anti-metastatic \[[@pone.0216085.ref068],[@pone.0216085.ref069]\], anti-inflammatory \[[@pone.0216085.ref070],[@pone.0216085.ref071]\], and antioxidant \[[@pone.0216085.ref072]\] activities. Recently celastrol was identified as a noncompetitive inhibitor of SidA production \[[@pone.0216085.ref054]\]. Inhibition of SidA production by celastrol is detrimental to *A*. *fumigatus* growth \[[@pone.0216085.ref054]\]. We observed inhibitory effects of celastrol on *A*. *fumigatus* metabolism as well ([Fig 6](#pone.0216085.g006){ref-type="fig"}). Since celastrol has numerous effects \[[@pone.0216085.ref068]--[@pone.0216085.ref071]\] it can't be excluded that effects on *A*. *fumigatus* are not solely owed to inhibition of siderophores production.

SidA-deficiency or addition of celastrol to *A*. *fumigatus* wildtype cultures resulted not only in reduced fungal growth \[[@pone.0216085.ref054]\], and reduced *A*. *fumigatus* biofilm metabolism ([Fig 6](#pone.0216085.g006){ref-type="fig"}), but also in increased sensitivity towards the iron chelator DFP. DFP is clinically used to treat iron overload, as in thalassemia major \[[@pone.0216085.ref073]\], but also interferes with iron needs of bacteria \[[@pone.0216085.ref074]\], and *A*. *fumigatus* biofilms \[[@pone.0216085.ref051]\]. Given that celastrol does not have unwanted effects on the host it might be quite useful in supporting anti-fungal therapy.

Previous studies have focused on *P*. *aeruginosa* products and their inhibition of *A*. *fumigatus*, at high *P*. *aeruginosa* product concentrations. Such studies have not considered the possible response of *A*. *fumigatus* at the onset of *P*. *aeruginosa* competition. We here show that *A*. *fumigatus* uses its siderophores to counter-balance iron denial by *P*. *aeruginosa*. *In vivo*, the winning microbe in this competition might be the one which unleashes its products first, and in the greatest quantity. *A*. *fumigatus* siderophores seem to also strengthen the fungus against certain types of therapy. Therefore, interference with siderophore production might boost existing therapy against *A*. *fumigatus*.

Supporting information {#sec019}
======================

###### Overview of the experimental setup.

Af: *Aspergillus fumigatus*; Afsup: planktonic *A*. *fumigatus* supernatant, Pa: *Pseudomonas*; Pasup: planktonic *P*. *aeruginosa* supernatant, PYOV: pyoverdine;

(TIF)

###### 

Click here for additional data file.

###### Gliotoxin content in Afsup is not likely to affect *P. aeruginosa*.

*P*. *aeruginosa* cells (5 x 10^7^ /ml) were incubated with planktonic supernatants (25%) derived from AF5322 wildtype, AFgliΔP (gliotoxin mutant), or AFgliPR (reversion of the gliotoxin mutant) at 37°C for 24h. Bacterial growth (A600: A), and pyoverdine (PYOV; A405) were measured, and relative pyoverdine concentration (B) was calculated using the quotient A405/A600. Statistics by t-Test: PA14 supernatant, not containing Afsup (white bar) vs. PA14 supernatants containing Afsup. Two or three asterisks = p ≤ 0.01 or p ≤ 0.001, respectively.

(TIF)

###### 

Click here for additional data file.

###### Reduction of nutrients affects bacterial growth, but does not result in protection of *A. fumigatus* from *P. aeruginosa* toxicity.

*P*. *aeruginosa* cells (5 x 10^7^ /ml) were incubated in RPMI 1640 medium containing 25% 10AFsup, or 25% sterile water, at 37°C for 24h. A: Bacterial growth (A600) was measured. Supernatants derived from A were tested for toxicity against *A*. *fumigatus* biofilm formation (XTT assay: B). Statistics by t-Test: A: PA14 supernatant prepared without Afsup or water addition (white bar) vs all other bars. B: RPMI (while bar) vs. all other bars. Other comparisons as indicated by the ends of the brackets. Two or three asterisks = p ≤ 0.01 or p ≤ 0.001, respectively.

(TIF)

###### 

Click here for additional data file.

###### Afsup induces pyoverdine and protects from *P. aeruginosa* anti-fungal activity.

A: RPMI was inoculated with PA14 wildtype or the PA14 mutant PaΔ*pvdD* (5x10^7^ cells/ml), with (black bars) or without (white bars) the presence of 25% 10AFsup, and incubated at 37°C for 24h. Pyoverdine production was measured. B: Samples produced in A were used in a BCAM assay, and compared to metabolism of 10AF forming biofilm in the presence of RPMI or 25% 10AFsup, incubated without bacteria. Statistics: t-Test, as indicated by the ends of the brackets. Two or three asterisks = p ≤ 0.01 or p ≤ 0.001, respectively.

(TIF)

###### 

Click here for additional data file.

###### TAFC and DF-TAFC are stable to prolonged heat treatment.

A 10AF BCAM assay was incubated with RPMI, TAFC \[10 μM\], DF-TAFC \[10 μM\], either fresh or heat treated (90°C for 30 min), and combined with pyoverdine (not heated) \[PYOV, 10 μM\]. Fungal metabolism was measured by XTT assay. Control (RPMI incubation without heat treatment) was regarded as 100%. Statistics: t-Test, comparison: PYOV without heat treatment vs. all other PYOV-containing bars. Other comparisons as indicated by the ends of the brackets. One, two or three asterisks = p ≤ 0.05, p ≤ 0.01 or p ≤ 0.001, respectively. Comparison of heat treatment of PYOV to unheated PYOV is also shown.

(TIF)

###### 

Click here for additional data file.

###### Data sets used in this study.

(PDF)

###### 

Click here for additional data file.
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:   *Aspergillus fumigatus*
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:   *P*. *Aeruginosa*
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:   pyoverdine

BCAM

:   metabolic assay of *A*. *fumigatus* biofilm formation on agar

DFP
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:   amphotericin B
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:   ferricrocin
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TAFC

:   triacetylfusarinine C
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